TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23442748

Group type: EXPERIMENTAL
Intervention: Screening and treatment of asymptomatic carriers with artemether-lumefantrine during community screening campaigns.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no treatment).
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Screening and treatment of asymptomatic carriers with artemether-lumefantrine during campaign 1.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Screening and treatment of asymptomatic carriers with artemether-lumefantrine during campaigns 2 and 3.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Screening and treatment of asymptomatic carriers with artemether-lumefantrine during campaign 4.
Number of subjects: 18
Study: 21470880

Group type: EXPERIMENTAL
Intervention: Calf compression during MRA
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional MRA without calf compression
Number of subjects: 61
Study: 18422947

Group type: COMPARATOR
Intervention: Aerobic cycling plus sham progressive resistance training (n=13)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sham cycling plus progressive resistance training (n=13)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Aerobic cycling plus progressive resistance training (n=14)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sham cycling plus sham progressive resistance training (n=12)
Number of subjects: 52
Study: 16411280

Group type: EXPERIMENTAL
Intervention: Time Domain Fitting (TDF) method
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Frequency Domain Analysis (FDA) method
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both TDF and FDA methods
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Monte Carlo simulations
Number of subjects: 72
Study: 12671888

Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone 200 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 10846910

Group type: EXPERIMENTAL
Intervention: Urapidil (0.4 mg/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lidocaine (1.5 mg/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both Urapidil and Lidocaine
Number of subjects: 40
Study: 9332475

Group type: COMPARATOR
Intervention: Normal cultures (without aphidicolin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cultures with aphidicolin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Breast cancer individuals in both types of cultures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Uterine cervix cancer individuals in both types of cultures
Number of subjects: 0
Study: 8401358

Group type: EXPERIMENTAL
Intervention: Propantheline 30 mg orally every 6 h for six doses
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29909565

Group type: EXPERIMENTAL
Intervention: Topical pimecrolimus, applied four times daily for 4 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Betamethasone cream, applied four times daily for 4 weeks
Number of subjects: 30
Study: 29656933

Group type: EXPERIMENTAL
Intervention: Bioelectrical Impedance Analysis (BIA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Skinfold Thickness Measurement (STM)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dual-Energy X-ray Absorptiometry (DXA)
Number of subjects: 30
Study: 27462136

Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5 mg daily for two weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 25169639

Group type: EXPERIMENTAL
Intervention: Surgical treatment for benign struma ovarii (25 cystectomies, 15 unilateral salpingo-oophorectomies, 2 bilateral salpingo-oophorectomies, 22 hysterectomies with salpingo-oophorectomy)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Surgical treatment for malignant struma ovarii (1 fertility-sparing staging surgery, 2 unilateral salpingo-oophorectomies, 1 hysterectomy with bilateral salpingo-oophorectomy)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Chemotherapy after surgery for malignant struma ovarii (2 patients)
Number of subjects: 68
Study: 22153890

Group type: EXPERIMENTAL
Intervention: Pertuzumab and trastuzumab plus docetaxel (group B)
Number of subjects: 417

Group type: COMPARATOR
Intervention: Trastuzumab plus docetaxel (group A)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Pertuzumab plus docetaxel (group D)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Pertuzumab and trastuzumab (group C)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 417

Group type: COMPARATOR
Intervention: Group C
Number of subjects: 417
Study: 20682679

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 1759

Group type: COMPARATOR
Intervention: Usual care (diabetes support and education [DSE])
Number of subjects: 1759
Study: 17878180

Group type: EXPERIMENTAL
Intervention: Probiotics (formula containing Bifidobacterium bifidum with Streptococcus thermophilus - 2.5 x 10(10) colony forming units)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Standard formula (control group)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 77
Study: 15753235

Group type: EXPERIMENTAL
Intervention: Modafinil (400 mg x 1)
Number of subjects: 12
Study: 12005316

Group type: COMPARATOR
Intervention: Normally developing children
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Children with spastic diplegia
Number of subjects: 17

Group type: COMPARATOR
Intervention: Normally developing adults
Number of subjects: 17
Study: 10610828

Group type: EXPERIMENTAL
Intervention: ABI group (clinical surveillance with distal pressure measurements)
Number of subjects: 344

Group type: COMPARATOR
Intervention: DD group (duplex scanning)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: ABI group (with protocol adherence)
Number of subjects: 344

Group type: COMPARATOR
Intervention: DD group (with protocol adherence)
Number of subjects: 344
Study: 7806030

Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control
Number of subjects: 7
Study: 1672679

Group type: EXPERIMENTAL
Intervention: BRL 26830A
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6806155

Group type: EXPERIMENTAL
Intervention: Intravenous mannitol (1 g/kg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Dexamethasone (32 mg stat, 8 mg qds)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 44
Study: 30482491

Group type: EXPERIMENTAL
Intervention: Maternal voice smoke alarms
Number of subjects: 176

Group type: COMPARATOR
Intervention: Conventional residential high‐frequency tone smoke alarm
Number of subjects: 176
Study: 28818998

Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) during -12° head-down tilt (HDT)
Number of subjects: 9

Group type: COMPARATOR
Intervention: -6° head-down tilt (HDT)
Number of subjects: 9

Group type: COMPARATOR
Intervention: -12° head-down tilt (HDT)
Number of subjects: 9

Group type: COMPARATOR
Intervention: -18° head-down tilt (HDT)
Number of subjects: 9

Group type: COMPARATOR
Intervention: -12° head-down tilt with 1% CO2
Number of subjects: 9
Study: 25327872

Group type: EXPERIMENTAL
Intervention: Sequential use of double‐balloon catheter and oral misoprostol
Number of subjects: 326

Group type: COMPARATOR
Intervention: Oral misoprostol alone
Number of subjects: 326
Study: 23388346

Group type: EXPERIMENTAL
Intervention: Breast-feeding (BF)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Standard control formula
Number of subjects: 91

Group type: COMPARATOR
Intervention: High-sn-2 palmitate formula
Number of subjects: 91
Study: 21067880

Group type: EXPERIMENTAL
Intervention: Iodine concentration of 370 mg I/mL (Group B)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Iodine concentration of 300 mg I/mL (Group A)
Number of subjects: 105
Study: 19308807

Group type: EXPERIMENTAL
Intervention: Add-on intraprostatic BoNT‐A injection (200-600 U of Botox)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Continued medical therapy (control group)
Number of subjects: 60
Study: 17350966

Group type: EXPERIMENTAL
Intervention: Webster-Stratton Incredible Years basic parenting programme, a 12 week group based intervention
Number of subjects: 153

Group type: COMPARATOR
Intervention: Wait listing (control)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Webster-Stratton Incredible Years basic parenting programme
Number of subjects: 153
Study: 15452006

Group type: EXPERIMENTAL
Intervention: Ads incorporating a prescription drug benefit box
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ads without a prescription drug benefit box
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General perception of benefit data in drug ads
Number of subjects: 0
Study: 11552869

Group type: EXPERIMENTAL
Intervention: Walking with a 2.5 cm shoe-lift
Number of subjects: 8

Group type: COMPARATOR
Intervention: Walking without a shoe-lift
Number of subjects: 8
Study: 9013360

Group type: EXPERIMENTAL
Intervention: Carpal tunnel syndrome patients (CTS)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 26
Study: 7833515

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 40
Study: 2971182

Group type: EXPERIMENTAL
Intervention: RU 41740
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30309327

Group type: EXPERIMENTAL
Intervention: Shenmai injection (SMI) 0.6 mL/kg administered intravenously from the time of anesthesia induction to the beginning of CPB.
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 88
Study: 29349214

Group type: EXPERIMENTAL
Intervention: Performance-based financing (PBF) program
Number of subjects: 0
Study: 25892174

Group type: EXPERIMENTAL
Intervention: Exposure and Response Prevention (ERP)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Youth coping and therapist interventions
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Youth-interfering behavior
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Youth-interfering behaviors
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Youth coping
Number of subjects: 43
Study: 23368948

Group type: EXPERIMENTAL
Intervention: Connective tissue graft (CTG)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Connective tissue graft plus resin-modified glass ionomer restoration (CTG+R)
Number of subjects: 36
Study: 21601343

Group type: EXPERIMENTAL
Intervention: CRQ-SAS (self-administered version)
Number of subjects: 40

Group type: COMPARATOR
Intervention: CRQ-IA (interviewer-administered version)
Number of subjects: 40
Study: 18468272

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections (BTX‐A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline placebo injections
Number of subjects: 20
Study: 16820551

Group type: EXPERIMENTAL
Intervention: Acetaminophen (4 g daily)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 14674906

Group type: EXPERIMENTAL
Intervention: Oral activated charcoal
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control period (no charcoal taken)
Number of subjects: 8
Study: 10791245

Group type: EXPERIMENTAL
Intervention: Pylorus‐preserving gastrectomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Distal gastrectomy with Billroth I anastomosis
Number of subjects: 50
Study: 8677191

Group type: EXPERIMENTAL
Intervention: Patients with arterial hypertension
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (27 healthy volunteers)
Number of subjects: 28
Study: 1803767

Group type: EXPERIMENTAL
Intervention: Live recombinant influenza vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6096154

Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ranitidine (300 mg/day)
Number of subjects: 12
Study: 29370813

Group type: EXPERIMENTAL
Intervention: Systems consultation intervention
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control clinics
Number of subjects: 8
Study: 27756281

Group type: EXPERIMENTAL
Intervention: Big White Wall (BWW) online platform for mental health self-management and peer support for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Big White Wall (BWW) online platform for mental health self-management and peer support for an additional 3 months (opt-in extension)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No additional intervention (opt-in extension control)
Number of subjects: 0
Study: 24855368

Group type: EXPERIMENTAL
Intervention: ERN/LRPT 1 g/20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SIMVA 10, 20, or 40 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ERN/LRPT 1 g/20 mg + SIMVA (10, 20, or 40 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated patients (baseline)
Number of subjects: 0
Study: 24165325

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioural tool
Number of subjects: 20
Study: 20003924

Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 182

Group type: COMPARATOR
Intervention: No influenza vaccination (Control)
Number of subjects: 182
Study: 18831744

Group type: EXPERIMENTAL
Intervention: Adalimumab 80 mg (two 40 mg injections at baseline followed by one 40 mg injection every other week from Week 1 to Week 15)
Number of subjects: 1205

Group type: EXPERIMENTAL
Intervention: Adalimumab 80 mg
Number of subjects: 1205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1205
Study: 15971040

Group type: EXPERIMENTAL
Intervention: Pattern A edema (found in 28 patients, 9.8%)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Pattern B edema (found in 10 patients, 3.5%)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Cadaver study (20 cadavers)
Number of subjects: 285
Study: 12944570

Group type: EXPERIMENTAL
Intervention: 3.0 mg of everolimus per day
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: 1.5 mg of everolimus per day
Number of subjects: 634

Group type: COMPARATOR
Intervention: Azathioprine (1.0 to 3.0 mg per kg per day)
Number of subjects: 634
Study: 10944065

Group type: EXPERIMENTAL
Intervention: Endomysium antibodies
Number of subjects: 1260

Group type: COMPARATOR
Intervention: IgA-gluten antibodies
Number of subjects: 1260

Group type: COMPARATOR
Intervention: IgG-gluten antibodies
Number of subjects: 1260
Study: 8937483

Group type: EXPERIMENTAL
Intervention: Regimen A (CDDP 16 mg/m2 for 5 days with 5-FU 700 mg/m2/day for 5 days)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Regimen B (CDDP 80 mg on day 1 with 5-FU 700 mg/m2/day for 5 days)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: UFT adjuvant chemotherapy (600 mg/day from day 1 to day 14) with CBDCA (350 mg/m2 on day 7)
Number of subjects: 42
Study: 1587073

Group type: EXPERIMENTAL
Intervention: Fenfluramine plus phentermine (60 mg fenfluramine plus 30 mg phentermine)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Fenfluramine plus phentermine (continued therapy)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Targeted intermittent therapy
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Augmented therapy
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Overall weight loss (all participants)
Number of subjects: 83
Study: 2858708

Group type: EXPERIMENTAL
Intervention: Thymopentin (TP-5) 50 mg 3 times a week for 3 consecutive weeks
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 30346511

Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: NNRTI-containing ART (after HIV-1 acquisition)
Number of subjects: 158
Study: 29492613

Group type: EXPERIMENTAL
Intervention: 0.56 g/kg alcohol in a vodka and tonic-mixed drink
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (tonic with 4 ml of vodka sprayed on top)
Number of subjects: 54
Study: 27869096

Group type: EXPERIMENTAL
Intervention: 21-Gy involved-field radiation therapy (IFRT)
Number of subjects: 716

Group type: COMPARATOR
Intervention: No additional therapy (control group)
Number of subjects: 716
Study: 25086593

Group type: EXPERIMENTAL
Intervention: 4-month physical exercise training programme including exercise training, resistance training, breathing exercises, and advice on increasing physical activity
Number of subjects: 102

Group type: COMPARATOR
Intervention: Usual care with advice on increasing physical activity and a sham treatment
Number of subjects: 102
Study: 23714670

Group type: EXPERIMENTAL
Intervention: EPI plus DEX (DEX:EPI = 10:1)
Number of subjects: 122

Group type: COMPARATOR
Intervention: EPI
Number of subjects: 122
Study: 20637390

Group type: EXPERIMENTAL
Intervention: Phloroglucinol (200 mg) with piroxicam (20 mg)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Placebo with piroxicam (20 mg)
Number of subjects: 253
Study: 19107268

Group type: EXPERIMENTAL
Intervention: Fissure sealing of 1 maxillary first molar and 1 mandibular first molar
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Fissure sealing of all first molars
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Fissure sealing of all molars and premolars on eruption
Number of subjects: 360

Group type: COMPARATOR
Intervention: No teeth sealed (control group)
Number of subjects: 360
Study: 16834644

Group type: EXPERIMENTAL
Intervention: Propiverine 20 mg once daily
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Propiverine 15 mg three times daily
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Oxybutynin 5 mg three times daily
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Propiverine 45 mg
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Oxybutynin 15 mg
Number of subjects: 77
Study: 12907830

Group type: EXPERIMENTAL
Intervention: Ferric hydroxide-polymaltose complex (Ferrum, Vifor, Switzerland) 6 mg/d for 3 months, then 3 mg/kg for 3 months
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ferrous sulfate complex (FerroSanol, Schwarz, Germany) 6 mg/d for 3 months, then 3 mg/kg for 3 months
Number of subjects: 25
Study: 11003764

Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem (n = 167)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Placebo (n = 163)
Number of subjects: 330
Study: 8975951

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid 300 mg orally twice a day
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg orally BID
Number of subjects: 59

Group type: COMPARATOR
Intervention: Untreated medical control group
Number of subjects: 59
Study: 1477017

Group type: EXPERIMENTAL
Intervention: Labetalol (up to 600 mg daily)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo (early-onset group)
Number of subjects: 144
Study: 4003495

Group type: EXPERIMENTAL
Intervention: Timolol eyedrops
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Timolol eyedrops with concomitant indomethacin
Number of subjects: 10
Study: 31324181

Group type: EXPERIMENTAL
Intervention: Cornelian cherry extract (320 mg/day of anthocyanins) for 12 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 80
Study: 29446471

Group type: EXPERIMENTAL
Intervention: Simplified technique (SG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional method (CG)
Number of subjects: 40
Study: 27555136

Group type: EXPERIMENTAL
Intervention: Combined femoral and sciatic nerve block (CFSNB)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Femoral nerve block (FNB)
Number of subjects: 68
Study: 24687251

Group type: EXPERIMENTAL
Intervention: Salbutamol/normal saline
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate and normal saline
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Salbutamol plus magnesium sulfate
Number of subjects: 56

Group type: COMPARATOR
Intervention: Magnesium sulfate
Number of subjects: 56
Study: 22980596

Group type: EXPERIMENTAL
Intervention: Endoscopic rubber band ligation (EBL) using Saeed multiband ligator
Number of subjects: 120

Group type: COMPARATOR
Intervention: Endoscopic injection sclerotherapy (EIS) using either ethanolamine oleate 5% or N‐butyl cyanoacrylate
Number of subjects: 120
Study: 20029189

Group type: EXPERIMENTAL
Intervention: Nicergoline (15 mg t.i.d.)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no nicergoline)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nicergoline (15 mg t.i.d.) in patients with bilateral basal ganglia involvement
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nicergoline (15 mg t.i.d.) in patients with no or unilateral basal ganglia involvement
Number of subjects: 50
Study: 17823084

Group type: COMPARATOR
Intervention: Exercise hyperthermia (E) - subjects exercised for two hours on a treadmill at 65% max in thermoneutral conditions, followed by 1-h recovery in thermoneutral conditions.
Number of subjects: 8

Group type: COMPARATOR
Intervention: Passive hyperthermia (PH) - subjects remained in a semi-recumbent position in a climatic chamber for two hours in hot conditions, followed by 1-h recovery in thermoneutral conditions.
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Control (C) - subjects remained in a sitting posture for three hours in thermoneutral conditions.
Number of subjects: 8
Study: 18720219

Group type: EXPERIMENTAL
Intervention: Pictorial encoding effects induced by the DRM task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: List-specific cues during encoding
Number of subjects: 0
Study: 15099665

Group type: EXPERIMENTAL
Intervention: Format A (questions on quantity and frequency of alcohol consumption first)
Number of subjects: 1213

Group type: COMPARATOR
Intervention: Format B (CAGE questions first)
Number of subjects: 1213
Study: 11298066

Group type: EXPERIMENTAL
Intervention: Methadone with efavirenz
Number of subjects: 11
Study: 9396885

Group type: EXPERIMENTAL
Intervention: Misoprostol 50 micrograms
Number of subjects: 103

Group type: COMPARATOR
Intervention: Prostaglandin E2 (dinoprostone) 3 mg
Number of subjects: 103
Study: 8186906

Group type: EXPERIMENTAL
Intervention: Almitrine bimesylate (AB) 50-100 mg/day
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Almitrine bimesylate (AB)
Number of subjects: 21